tert-butyl (S)-2-(((tert-butoxycarbonyl)-oxy)methyl)-5-oxopyrrolidine-1-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: tert-butyl (S)-2-(((tert-butoxycarbonyl)-oxy)methyl)-5-oxopyrrolidine-1-carboxylate
• 英文别名: (S)-1-tert-butoxycarbonyl-5-tert-butoxycarbonyloxymethyl-pyrrolidin-2-one；(S)-tert-butyl 2-(((tert-butoxycarbonyl)-oxy)methyl)-5-oxopyrrolidine-1-carboxylate；tert-butyl (2S)-2-[(2-methylpropan-2-yl)oxycarbonyloxymethyl]-5-oxopyrrolidine-1-carboxylate
• 化学式: C₁₅H₂₅NO₆
• 分子量: 315.367
• InChiKey: FGOZZCHTZNQRST-JTQLQIEISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  22
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  82.1
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  tert-butyl (S)-2-(((tert-butoxycarbonyl)-oxy)methyl)-5-oxopyrrolidine-1-carboxylate 、 溴乙腈 在 lithium diisopropyl amide 作用下， 以 四氢呋喃 为溶剂， 反应 0.83h， 以77%的产率得到tert-butyl (5S)-5-(((tert-butoxycarbonyl)oxy)methyl)-3-(cyanomethyl)-2-oxopyrrolidine-1-carboxylate
  参考文献：
  名称：

  Bicyclic-Fused Heteroaryl or Aryl Compounds

  摘要：

  所述化合物的异构体和药学上可接受的盐已被披露，其中所述化合物具有如规范中定义的Ia式结构。相应的药物组合物、治疗方法、合成方法和中间体也已被披露。

  公开号：

  US20150284405A1
• 作为产物：
  描述：

  二碳酸二叔丁酯 、 L-焦谷氨醇 在 4-二甲氨基吡啶 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 以61.3%的产率得到tert-butyl (S)-2-(((tert-butoxycarbonyl)-oxy)methyl)-5-oxopyrrolidine-1-carboxylate
  参考文献：
  名称：

  SYNTHESIS OF A NEW CHIRAL AMINE:(S)-5,5-DIMETHYL-2-METHOXYMETHYL-PYRROLIDINE

  摘要：

  The title compound, a potential 'quat' auxiliary,was prepared from (S)-glutamic acid derivatives like (S)-N-Benzyl-5-methoxymethyl-2pyrrolidinone 1. Other routes starting from (S)-pyroglutamic acid in an attempt to bypass N-Aryl compounds like 1 were also tested, but. have not rendered the expected results yet.

  DOI：

  10.1081/scc-100103258

文献信息

• BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS
  申请人：Pfizer Inc.

  公开号：EP3536685A1

  公开（公告）日：2019-09-11

  Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment of autoimmune and inflammatory diseases associated with Interleukin-1 Receptor Associated Kinase (IRAK), methods of synthesis, and intermediates are also disclosed.

  本发明公开了化合物、同系物和药学上可接受的盐，其中化合物具有式 Ia 的结构、 的结构。还公开了相应的药物组合物、与白细胞介素-1受体相关激酶（IRAK）相关的自身免疫性和炎症性疾病的治疗方法、合成方法和中间体。
• Bicyclic-fused heteroaryl or aryl compounds
  申请人：Pfizer Inc.

  公开号：US10329302B2

  公开（公告）日：2019-06-25

  Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  本发明公开了化合物、化合物的同系物和药学上可接受的盐，其中化合物具有说明书中定义的式 Ia 结构。 还公开了相应的药物组合物、治疗方法、合成方法和中间体。
• New Strategy for the Stereoselective Synthesis of Fluorinated β-Amino Acids
  作者：Santos Fustero、Belén Pina、Esther Salavert、Antonio Navarro、M. Carmen Ramírez de Arellano、Antonio Simón Fuentes

  DOI：10.1021/jo025621k

  日期：2002.7.1

  Racemic and chiral nonracemic alpha-substituted and alpha-unsubstituted beta-fluoroalkyl beta-amino acid derivatives 6 and 9 have been synthesized in two steps starting from fluorinated imidoyl chlorides 1 and ester enolates. This approach is based on the chemical reduction of previously obtained gamma-fluorinated beta-enamino esters 4 by using ZnI2/NaBH4 in a nonchelated aprotic medium (dry CH2Cl2) as the reducing agent. A metal-chelated six-membered model has been suggested to explain the stereochemical outcome of the reduction reaction. The process takes place with high yields and with moderate to good diastereoselectivity. The best results related to diastereoselective reduction of chiral beta-enamino esters 4 were provided by the use of (-)-8-phenylmenthol as a chiral auxiliary.
• US9458168B2
  申请人：——

  公开号：US9458168B2

  公开（公告）日：2016-10-04
• US9879022B2
  申请人：——

  公开号：US9879022B2

  公开（公告）日：2018-01-30